Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults
Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicr...
Saved in:
| Published in | Journal of Korean Medical Science Vol. 37; no. 9; pp. e70 - 6 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Korean Academy of Medical Sciences
2022
The Korean Academy of Medical Sciences 대한의학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1011-8934 1598-6357 1598-6357 |
| DOI | 10.3346/jkms.2022.37.e70 |
Cover
| Abstract | Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND
) titers in serum samples. ND
titers against the omicron variant (median [interquartile range], 5.3 [< 5.0-12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7-294.0]) and delta (24.3 [14.3-81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND
titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND
titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants (
< 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant. |
|---|---|
| AbstractList | Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND50) titers in serum samples. ND50 titers against the omicron variant (median [interquartile range], 5.3 [< 5.0-12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7-294.0]) and delta (24.3 [14.3-81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND50 titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND50 titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants (P < 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant.Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND50) titers in serum samples. ND50 titers against the omicron variant (median [interquartile range], 5.3 [< 5.0-12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7-294.0]) and delta (24.3 [14.3-81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND50 titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND50 titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants (P < 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant. Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND 50 ) titers in serum samples. ND 50 titers against the omicron variant (median [interquartile range], 5.3 [< 5.0–12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7–294.0]) and delta (24.3 [14.3–81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND 50 titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND 50 titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants ( P < 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant. Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/ KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND50) titers in serum samples. ND50 titers against the omicron variant (median [interquartile range], 5.3 [< 5.0–12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7–294.0]) and delta (24.3 [14.3–81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND50 titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND50 titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants (P < 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant. KCI Citation Count: 0 Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND ) titers in serum samples. ND titers against the omicron variant (median [interquartile range], 5.3 [< 5.0-12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7-294.0]) and delta (24.3 [14.3-81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants ( < 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant. |
| Author | Gayeon Kim Min-Kyung Kim Jun-Sun Park Jaehyun Jeon Youn Young Choi Hee-Chang Jang Ho Kyung Sung Ji Hwan Bang Kyung-Shin Lee Yoo-kyoung Lee Ki-hyun Chung Jihye Um Myoung-don Oh Byung Chul Kim |
| AuthorAffiliation | 1 Research Institute of Public Health, National Medical Center, Seoul, Korea 3 Department of Infectious Diseases, National Medical Center, Seoul, Korea 5 Division of Infectious Diseases, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea 2 Department of Pediatrics, National Medical Center, Seoul, Korea 4 National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea 6 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea |
| AuthorAffiliation_xml | – name: 4 National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea – name: 2 Department of Pediatrics, National Medical Center, Seoul, Korea – name: 5 Division of Infectious Diseases, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea – name: 1 Research Institute of Public Health, National Medical Center, Seoul, Korea – name: 6 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – name: 3 Department of Infectious Diseases, National Medical Center, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Jihye orcidid: 0000-0001-8924-9862 surname: Um fullname: Um, Jihye organization: Research Institute of Public Health, National Medical Center, Seoul, Korea – sequence: 2 givenname: Youn Young orcidid: 0000-0001-8749-0951 surname: Choi fullname: Choi, Youn Young organization: Research Institute of Public Health, National Medical Center, Seoul, Korea., Department of Pediatrics, National Medical Center, Seoul, Korea – sequence: 3 givenname: Gayeon orcidid: 0000-0001-9788-9800 surname: Kim fullname: Kim, Gayeon organization: Department of Infectious Diseases, National Medical Center, Seoul, Korea – sequence: 4 givenname: Min-Kyung orcidid: 0000-0003-0473-2797 surname: Kim fullname: Kim, Min-Kyung organization: Department of Infectious Diseases, National Medical Center, Seoul, Korea – sequence: 5 givenname: Kyung-Shin orcidid: 0000-0003-3451-3763 surname: Lee fullname: Lee, Kyung-Shin organization: Research Institute of Public Health, National Medical Center, Seoul, Korea – sequence: 6 givenname: Ho Kyung orcidid: 0000-0002-1207-0298 surname: Sung fullname: Sung, Ho Kyung organization: Research Institute of Public Health, National Medical Center, Seoul, Korea – sequence: 7 givenname: Byung Chul orcidid: 0000-0002-9606-5153 surname: Kim fullname: Kim, Byung Chul organization: National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea – sequence: 8 givenname: Yoo-kyoung orcidid: 0000-0002-5639-8754 surname: Lee fullname: Lee, Yoo-kyoung organization: National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea – sequence: 9 givenname: Hee-Chang orcidid: 0000-0002-3407-8493 surname: Jang fullname: Jang, Hee-Chang organization: National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea – sequence: 10 givenname: Ji Hwan orcidid: 0000-0002-7628-1182 surname: Bang fullname: Bang, Ji Hwan organization: Division of Infectious Diseases, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea – sequence: 11 givenname: Ki-hyun orcidid: 0000-0002-7100-2519 surname: Chung fullname: Chung, Ki-hyun organization: Department of Pediatrics, National Medical Center, Seoul, Korea – sequence: 12 givenname: Myoung-don orcidid: 0000-0002-2344-7695 surname: Oh fullname: Oh, Myoung-don organization: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 13 givenname: Jun-Sun orcidid: 0000-0003-2363-0390 surname: Park fullname: Park, Jun-Sun organization: Research Institute of Public Health, National Medical Center, Seoul, Korea – sequence: 14 givenname: Jaehyun orcidid: 0000-0002-1725-8468 surname: Jeon fullname: Jeon, Jaehyun organization: Research Institute of Public Health, National Medical Center, Seoul, Korea., Department of Infectious Diseases, National Medical Center, Seoul, Korea |
| BackLink | https://cir.nii.ac.jp/crid/1874242817717311360$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/35257525$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002819149$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9Uk1v0zAYjtAQ2wp3TsgHDnBI8UcS2xektAyoNK3SVipxshzHbb2m9rAdpPI7-ME4bYeAAwf7teTn49X7PpfZmXVWZ9lLBMeEFNW7--0ujDHEeEzoWFP4JLtAJWd5RUp6lt4QoZxxUpxnlyHcQ4jLEpNn2TkpcUnTuch-TpwLUXswuVmgCjcYTOfL2YcccbCUShkro3EWzKzyWgYdwI3uo5ed-WHsGtQ2msa1e7AwSSOAei2NDRHEjQZ39e1dPnXLHIP5ziifVJbSG2kjMBZMXNyAr65PItK24Kprte_2oG77Lobn2dOV7IJ-caqj7MvHq8X0c349_zSb1te5Sr3HHDeUYFQVCPICEg2lamArGVvRBlFI2obKCmJe4Ia3BW9bxXmjqhWjELKy5YiMsrdHXetXYquMcNIc6tqJrRf17WImOCesJDRh3x-xD32z063SdhiDePBmJ_3-wPz7x5pN0vkuGIeIscHszUnAu2-9DlHsTFC666TVrg8CV8kFFYPbKHv1p9dvk8e1JUB1BKSxhuD1SigTD5tK1qYTCIohH2LIhxjyIQgVKR-JCP8hPmr_h_L6NCRjks1wI0YLXGCGKEWpZ0QqSH4B39_H1g |
| CitedBy_id | crossref_primary_10_3947_ic_2022_0132 crossref_primary_10_7759_cureus_29296 crossref_primary_10_3390_ijms24119753 crossref_primary_10_3390_vaccines10122102 crossref_primary_10_4110_in_2023_23_e33 crossref_primary_10_1002_slct_202201380 crossref_primary_10_1097_INF_0000000000004709 crossref_primary_10_3346_jkms_2022_37_e209 crossref_primary_10_1051_mmnp_2024005 crossref_primary_10_7774_cevr_2023_12_2_116 |
| Cites_doi | 10.5501/wjv.v5.i2.85 10.3390/v14020294 10.1093/cid/ciab381 10.1136/bmj.n3062 10.1038/s41591-021-01377-8 10.1016/j.cell.2021.01.007 10.1038/s41586-021-04389-z 10.1016/j.cell.2021.12.032 10.1016/j.cell.2021.06.020 10.1016/j.cell.2021.12.033 10.1136/bmj.n3079 |
| ContentType | Journal Article |
| Copyright | 2022 The Korean Academy of Medical Sciences. 2022 The Korean Academy of Medical Sciences. 2022 The Korean Academy of Medical Sciences |
| Copyright_xml | – notice: 2022 The Korean Academy of Medical Sciences. – notice: 2022 The Korean Academy of Medical Sciences. 2022 The Korean Academy of Medical Sciences |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| DOI | 10.3346/jkms.2022.37.e70 |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1598-6357 |
| EndPage | 6 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9938537 PMC8901881 35257525 10_3346_jkms_2022_37_e70 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: National Medical Center grantid: NMC2021-Commissioned Research Program-01 – fundername: National Institute of Infectious Diseases grantid: 2021ER230400 – fundername: ; grantid: NMC2021-Commissioned Research Program-01 – fundername: ; grantid: 2021ER230400 |
| GroupedDBID | --- 29K 2WC 5-W 5GY 8JR 8XY 9ZL ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CS3 D-I DIK DU5 E3Z EBS EF. EJD F5P FRP GROUPED_DOAJ GX1 HYE KQ8 M48 O5R O5S OK1 OVT PGMZT RNS RPM RYH TR2 W2D XSB 3O- 53G AAYXX ADRAZ CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| ID | FETCH-LOGICAL-c525t-2b732164109403e0acb0da88f7b1703db7a602942b9d49ddc99bc6f870085d913 |
| IEDL.DBID | M48 |
| ISSN | 1011-8934 1598-6357 |
| IngestDate | Sun Mar 09 07:52:50 EDT 2025 Thu Aug 21 13:36:18 EDT 2025 Thu Jul 10 23:37:07 EDT 2025 Mon Jul 21 06:06:21 EDT 2025 Tue Jul 01 01:26:33 EDT 2025 Thu Apr 24 23:02:56 EDT 2025 Thu Jun 26 22:36:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | COVID-19 Vaccine Antibodies Omicron Variant Immunity Republic of Korea |
| Language | English |
| License | 2022 The Korean Academy of Medical Sciences. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c525t-2b732164109403e0acb0da88f7b1703db7a602942b9d49ddc99bc6f870085d913 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Jihye Um and Youn Young Choi contributed equally to this work. |
| ORCID | 0000-0001-8749-0951 0000-0002-3407-8493 0000-0002-1207-0298 0000-0002-9606-5153 0000-0003-3451-3763 0000-0002-7100-2519 0000-0002-1725-8468 0000-0002-7628-1182 0000-0002-5639-8754 0000-0003-2363-0390 0000-0001-8924-9862 0000-0002-2344-7695 0000-0001-9788-9800 0000-0003-0473-2797 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2022.37.e70 |
| PMID | 35257525 |
| PQID | 2637314385 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9938537 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8901881 proquest_miscellaneous_2637314385 pubmed_primary_35257525 crossref_citationtrail_10_3346_jkms_2022_37_e70 crossref_primary_10_3346_jkms_2022_37_e70 nii_cinii_1874242817717311360 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-00-00 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – year: 2022 text: 2022-00-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of Korean Medical Science |
| PublicationTitleAlternate | J Korean Med Sci |
| PublicationYear | 2022 |
| Publisher | Korean Academy of Medical Sciences The Korean Academy of Medical Sciences 대한의학회 |
| Publisher_xml | – name: Korean Academy of Medical Sciences – name: The Korean Academy of Medical Sciences – name: 대한의학회 |
| References | Grabowski (10.3346/jkms.2022.37.e70_ref8) 2022; 14 Bartha (10.3346/jkms.2022.37.e70_ref4) Schmidt (10.3346/jkms.2022.37.e70_ref19) Andrews (10.3346/jkms.2022.37.e70_ref10) 2021 Müller (10.3346/jkms.2022.37.e70_ref17) 2021; 73 Gruell (10.3346/jkms.2022.37.e70_ref12) 2022 Pulliam (10.3346/jkms.2022.37.e70_ref3) Khoury (10.3346/jkms.2022.37.e70_ref11) 2021; 27 Garcia-Beltran (10.3346/jkms.2022.37.e70_ref13) 2022; 185 Sette (10.3346/jkms.2022.37.e70_ref15) 2021; 184 Planas (10.3346/jkms.2022.37.e70_ref18) 2022; 602 Mahase (10.3346/jkms.2022.37.e70_ref14) 2021; 375 Mahase (10.3346/jkms.2022.37.e70_ref9) 2021; 375 Liu (10.3346/jkms.2022.37.e70_ref5) 2021; 184 Hoffmann (10.3346/jkms.2022.37.e70_ref2) 2022; 185 10.3346/jkms.2022.37.e70_ref6 Li (10.3346/jkms.2022.37.e70_ref16) 2021 10.3346/jkms.2022.37.e70_ref1 Ramakrishnan (10.3346/jkms.2022.37.e70_ref7) 2016; 5 |
| References_xml | – volume: 5 start-page: 85 issue: 2 year: 2016 ident: 10.3346/jkms.2022.37.e70_ref7 publication-title: World J Virol doi: 10.5501/wjv.v5.i2.85 – volume: 14 start-page: 294 issue: 2 year: 2022 ident: 10.3346/jkms.2022.37.e70_ref8 publication-title: Viruses doi: 10.3390/v14020294 – year: 2021 ident: 10.3346/jkms.2022.37.e70_ref16 publication-title: bioRxiv – ident: 10.3346/jkms.2022.37.e70_ref19 publication-title: medRxiv – ident: 10.3346/jkms.2022.37.e70_ref3 publication-title: medRxiv – volume: 73 start-page: 2065 issue: 11 year: 2021 ident: 10.3346/jkms.2022.37.e70_ref17 publication-title: Clin Infect Dis doi: 10.1093/cid/ciab381 – volume: 375 start-page: n3062 issue: 3062 year: 2021 ident: 10.3346/jkms.2022.37.e70_ref9 publication-title: BMJ doi: 10.1136/bmj.n3062 – volume: 27 start-page: 1205 issue: 7 year: 2021 ident: 10.3346/jkms.2022.37.e70_ref11 publication-title: Nat Med doi: 10.1038/s41591-021-01377-8 – start-page: 1 year: 2022 ident: 10.3346/jkms.2022.37.e70_ref12 publication-title: Nat Med – volume: 184 start-page: 861 issue: 4 year: 2021 ident: 10.3346/jkms.2022.37.e70_ref15 publication-title: Cell doi: 10.1016/j.cell.2021.01.007 – volume: 602 start-page: 671 issue: 7898 year: 2022 ident: 10.3346/jkms.2022.37.e70_ref18 publication-title: Nature doi: 10.1038/s41586-021-04389-z – volume: 185 start-page: 447 issue: 3 year: 2022 ident: 10.3346/jkms.2022.37.e70_ref2 publication-title: Cell doi: 10.1016/j.cell.2021.12.032 – volume: 184 start-page: 4220 issue: 6 year: 2021 ident: 10.3346/jkms.2022.37.e70_ref5 publication-title: Cell doi: 10.1016/j.cell.2021.06.020 – volume: 185 start-page: 457 issue: 3 year: 2022 ident: 10.3346/jkms.2022.37.e70_ref13 publication-title: Cell doi: 10.1016/j.cell.2021.12.033 – ident: 10.3346/jkms.2022.37.e70_ref4 publication-title: medRxiv – volume: 375 start-page: n3079 issue: 3079 year: 2021 ident: 10.3346/jkms.2022.37.e70_ref14 publication-title: BMJ doi: 10.1136/bmj.n3079 – ident: 10.3346/jkms.2022.37.e70_ref1 – ident: 10.3346/jkms.2022.37.e70_ref6 – year: 2021 ident: 10.3346/jkms.2022.37.e70_ref10 publication-title: medRxiv |
| SSID | ssj0025523 ssib044744820 ssib058493239 |
| Score | 2.3401585 |
| Snippet | Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant... |
| SourceID | nrf pubmedcentral proquest pubmed crossref nii |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e70 |
| SubjectTerms | Adult Aged Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine Brief Communication COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Humans SARS-CoV-2 Vaccination 의학일반 |
| Title | Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults |
| URI | https://cir.nii.ac.jp/crid/1874242817717311360 https://www.ncbi.nlm.nih.gov/pubmed/35257525 https://www.proquest.com/docview/2637314385 https://pubmed.ncbi.nlm.nih.gov/PMC8901881 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002819149 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Korean Medical Science, 2022, 37(9), , pp.1-6 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwELZgkRAXxJssbGUQFw4psfNwckAoLbvagtqV2Lbam2XH6RLaTZY0lSi_gx_MTJJtKarg0PQQx047Y8_3ecYzhLwRCr11yrUDkRrbMx63daiBuLpgbA1AiqQuBjMcBacT79OFf7E9Ht3-gcu91A7rSU3KRffH9_UHmPDvkXG66KGcX2Hibc67ruimAgj8HbBLAVKx4Rbse54AKrIFR2B5AbtgTsyWnvk-b8LxGbPBinuNU3PvCDtG7HaeZXgtZ_tQ6t_Bln9Yr5MH5H4LO2nc6MlDcuubekTuDlvH-mPyq1fgaY-S9kZjFnDNaf9sOvhos4hOVQJtagFSWE0wiD1d0lG6qvdIfoLpo3FeZbowazrGA81LGl-qDGAnBXBJz-Mv53a_mNqcnl1h9F8OPYLW5xXNctoDRaH1ikNVbugx1gxfrGmMWUGWT8jk5HjcP7Xbgg124nO_srkWLgf-xTApn5s6KtGOUWE4E5rBymK0UIHDI4_ryHiRMUkU6SSYwZIBwM9EzH1KDvIiT58TijAGn-dMAwVNAuUIxTD7WMhUalzHIu9uJCCTNps5FtVYSGA1KDOJMpMoM-kKCTKzyNvNE9dNJo9_tD0CoULHeMWqhQBkQiYwYgFr4MD91yBuOU8yiem58fuykPNSAgkZSIB8AIKERV7daIOEOYuOGJWnxQpGClzoyINWFnnWaMfmler0tPCxiNjRm00DHHD3Tp59rfOCh4DtwpAd_uflX5B7-FObfaSX5KAqV-kRIKtKd4BTDD536n2JTj15fgMuDRgr |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Booster+BNT162b2+COVID-19+Vaccination+Increases+Neutralizing+Antibody+Titers+Against+the+SARS-CoV-2+Omicron+Variant+in+Both+Young+and+Elderly+Adults&rft.jtitle=Journal+of+Korean+Medical+Science&rft.au=Jihye+Um&rft.au=Youn+Young+Choi&rft.au=Gayeon+Kim&rft.au=Min-Kyung+Kim&rft.date=2022&rft.pub=Korean+Academy+of+Medical+Sciences&rft.issn=1011-8934&rft.eissn=1598-6357&rft.volume=37&rft_id=info:doi/10.3346%2Fjkms.2022.37.e70 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon |